CVM-1118 not checked

TaiRx, Inc. · TRX-818 · TRX-818 ER

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
3 active
5 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Patients will initially receive CVM-1118 orally twice daily at 200 mg per dose (400 mg total daily dose). Patients who tolerate this dose for at least 2 Cycles will have the option of increasing the dose of CVM-1118 to 300 mg BID (600 mg total daily dose) if specific criteria are met.”In the company’s words, NCT03600233 on ClinicalTrials.gov
Tested for
Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor, Gastro-enteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm, Neuroendocrine Carcinoma, Hepatocellular Carcinoma, Advanced Cancer, HCC - Hepatocellular Carcinoma
Main trialPhase 2
“CVM-1118 (TRX-818) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objectives of the phase 2 study is to further investigate the efficacy of CVM-1118 for patients with advanced neuroendocrine tumors.”In the company’s words, NCT03600233 on ClinicalTrials.gov
Other names
TRX-818 · TRX-818 ER

Other drugs for Neuroendocrine Tumors

All 244 drugs for Neuroendocrine Tumors

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 30 Sep 2024 Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
Phase 2Recruiting 31 Dec 2026 CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
Phase 2Recruiting 31 Dec 2027 A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
Phase 2Terminated 16 Nov 2021 CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
Phase 1Completed 8 Feb 2021 Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow CVM-1118

Following is part of Solo: you see every change to CVM-1118 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in